期刊文献+

肿瘤细胞裂解物联合化脓性链球菌裂解物的抗肿瘤作用 被引量:1

Anti-tumor immunity of tumor cell lysate combined with group A streptococcus lysate induce in mice
下载PDF
导出
摘要 目的:研究化脓性链球菌裂解物与肿瘤细胞裂解物联用,抑制荷瘤小鼠肿瘤的生长。方法:自行制备了化脓性链球菌裂解物制剂,通过体外及动物实验测定其抗肿瘤效应。以BALB/c小鼠EMT6乳腺癌为模型,观察了链球菌制剂联合肿瘤细胞裂解物对荷瘤小鼠肿瘤生长的影响。结果:自行制备的化脓性链球菌在体外可以刺激小鼠脾细胞的增殖,且能抑制多种肿瘤细胞(EMT6、B16、A549)的增殖,二者联用对每只荷瘤小鼠的肿瘤体积都有较强的抑制作用(P<0.05)。结论:化脓性链球菌裂解物与肿瘤细胞裂解物联用可以抑制荷瘤小鼠肿瘤的生长。 Objective: To develop new vaccine for treatment of breast cancer. Methods : We have prepared the Group A Strep- tococcus pyogenes (GAS) lyaste and tumor cell lysate and evaluated their anti-tumor activity in vitro and in a breast cancer mouse model. Results : Interestingly, GAS lysate, prepared in this study, showed a vigorous activity on the stimulation the proliferation of mouse spleen cells and inhibition of the growth of variety of tumor cells in vitro, such as EMT6, B16 and A549. In addition, the mixture of GAS lysate and tumor cell lysate could significantly inhibit tumor growth in mice treated with EMT6 cell ( P〈0. 05 ). Conclusion : The data suggest that the mixture of GAS lysate plus tumor cell lysate might be developed into a candidate tumor vaccine for the treatment of breast cancer
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第9期1204-1207,1212,共5页 Chinese Journal of Immunology
基金 国家自然科学基金(No.31270982)
关键词 化脓性链球菌 肿瘤细胞裂解物 抗肿瘤 Group A Streptococcus pyogenes (GAS) Tumor cell lysate Anti-tumor
  • 相关文献

参考文献16

  • 1Coley WB. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases [ J ]. Am J Med Sci, 1893,105:487-511.
  • 2Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus [ J ]. Am J Med Sci,1906,131:375-430.
  • 3Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research : a historical perspective [ J] Pharmacol Ther, 1994,64:529-564.
  • 4Suzuki S, Shinohara N, Harabayashi T, et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications [ J ]. Int J Clin Oncol, 2002,7 : 289-293.
  • 5Ynng-Chie Lee, Shi-Ping Luh, Rong-Mou Wu, Chun-Jean Lee Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection [J]. Cancer Immunol Immunother, 1994,39:269-274.
  • 6Li X, Bukawa H, Hirota M, et al. Novel OK-432-conjugated tumor vaccines induce tumor-specific immunity against murine tongue cancer [ J ]. J Dent Res,2003,82 ( 8 ) : 636-640.
  • 7Jong-Lyel Roh, Hyo Sun Kim. Primary treatment of pediatric plunging ranula with nonsurgical selerotherapy using 0K-432 (Picibanil) [J]. Inter J Pediatric Otorhinolaryngol,2008,72(9) , 1405-1410.
  • 8Giguere CM, Bauman NM, Sato Y, et al. Greinwald JH treatment of lymphangiomas with 0K-432 (Picibanil) selerotherapy: a prospective multi-institutional trial [ J ]. Archives Otolaryngol- Head & Neck Surg,2002,128(10) :31-36.
  • 9Kai S, Tanaka J, Nomoto K, et al. Studies on the immunop- otentiating effects of a streptococcal preparation, OK- 432. I. Enhance-ment of T cell-mediated immune responses of mice [ J]. Clin Exp Immunol, 1979,37:98-105.
  • 10Osbimi K, Kano S, Takaku F, et aL Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK432 [ J ]. J Natl Cancer Inst, 1980,65 : 1265-1269.

二级参考文献4

共引文献2

同被引文献13

  • 1Mackiewicz J, Kazimierezak U, Kotlarski M, et aL Cellular vaccines modified with Hyper IL6 or Hyper ILl 1 combined with doeetaxel in an orthotopic prostate cancer model [ J ]. Anticancer Res,2015,35 (6) :3275 -3288.
  • 2Xu M, Xing Y, Zhou L, et al. Improved efficacy of therapeutic vac- cination with viable human umbilical vein endothelial cells against routine melanoma by introduction of 01(432 as adjuvant : J J. Tumour Biol,2013,34(3) :1399 - 1408.
  • 3Muller I, Hartmann D, Oertel J, et al. Static image analysis as new approach for the characterization of tumor cell lysate used in den- dritic cell vaccine preparation [ J ]. Transfus Med Hemother, 2015, 42(2) :122 - 128.
  • 4Gonz61ez FE, Gleisner A, Falc6n - Beas F, et al. Tumor cell lysates as immunogenic sources for cancer vaccine design[ J]. Hum Vaccin lmmunother,2014,10 ( 11 ) : 3261 - 3269.
  • 5Ribas A, Butterfield LH, GlaspyJA, et al. Current developments in cancer vaccines and cellular immunotherapy [ J ]. J Clin Oncol, 2003,21 (12) :2415 -2432.
  • 6Xu M, Zhou L, Zhang P, et al. Enhanced antitumor efficacy by com- bination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate - based vaccine [ J ]. Tumour Biol, 2013,34(5 ) :3173 - 3182.
  • 7Lin B,Zhao H,Fan J,et al. B16 cell lysates plus polyinosinic - cyt- idylie acid effectively eradicate melanoma in a mouse model by act- ing as a prophylactic vaccine [ J ]. Mol Med Rep,2014,10 (2) :911 -916.
  • 8Wang X, Bayer ME, Chen X, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autolo- gous irradiated tumor stem cells in hepatitis B - positive patients with hepatoeellular carcinoma [ J ]. J Surg Oncol, 2015,111 ( 7 ) : 862 - 867.
  • 9S Hong, H Li, J Qian, et al. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more po- tent tumour antigens than idiotype protein to promote anti - tumour immunity[ J]. Clin Exp Immunol,2012,170(2) : 167 -177.
  • 10Sirisha P,Sanjeeb KS,Rama SV. Targeted therapy of cancer using diphtheria toxin -derived immune toxins [ J ]. Drug Discov Today, 2008,13(17 - 18) :807 -815.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部